Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products

Key facts

Sponsor

St. Jude Children's Research Hospital

Principal Investigator

Stephen Gottschalk, MD, MD

St. Jude Children's Research Hospital

Intervention

Venipuncture(procedure)

Enrollment

41 enrolled

Eligibility

All sexes

Timeline

2007 – 2024

Study locations (1)

• St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for T-B+ severe combined immunodeficiency

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE1, PHASE2NCT06851767
  Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
  National Institute of Allergy and Infectious Diseases (NIAID)
• ACTIVE NOT RECRUITINGPHASE2NCT03619551
  Conditioning SCID Infants Diagnosed Early
  Center for International Blood and Marrow Transplant Research
• RECRUITINGPHASE1, PHASE2NCT01306019
  Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
  National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for T-B+ severe combined immunodeficiency →